Swedish radiation therapy firm Elekta has received U. S. Food and Drug Administration 510(k) clearance for its PrecisePlan intensity modulated radiation therapy (IMRT) product. The Stockholm firm said the system utilizes an aperture-based inverse planning technique developed by Thomas Jefferson University Hospital in Philadelphia. The protocol creates geometric or dosimetric field segments that conform to the planning target volume while shielding healthy organs.
By AuntMinnie.com staff writersOctober 9, 2002
Related Reading
Elekta inks deal with JPC, July 12, 2002
Elekta unveils respiratory immobilization technique, March 27, 2002
Elekta brings gamma knife to Canada, March 12, 2002
Elekta lands large radiotherapy orders, August 23, 2001
Elekta and ADAC join forces for IMRT system distribution, July 19, 2001
Copyright © 2002 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
